A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa.

Trial Profile

A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Ropinirole (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 Apr 2012 Actual patient number of the extension trial (NCT01536574) is 295 as reported by ClinicalTrials.gov.
    • 27 Apr 2012 Actual patient number of the extension trial (NCT01536574) is 295 as reported by ClinicalTrials.gov.
    • 27 Apr 2012 Status of the extension trial (NCT01536574) changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top